- Home
- RCKY vs ENGN Comparison
RCKY vs ENGN Comparison
Compare RCKY & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCKY
- ENGN
- Stock Information
- Founded
- RCKY 1932
- ENGN 1999
- Country
- RCKY United States
- ENGN Canada
- Employees
- RCKY N/A
- ENGN N/A
- Industry
- RCKY Shoe Manufacturing
- ENGN
- Sector
- RCKY Consumer Discretionary
- ENGN
- Exchange
- RCKY Nasdaq
- ENGN Nasdaq
- Market Cap
- RCKY 174.1M
- ENGN 191.1M
- IPO Year
- RCKY 1993
- ENGN N/A
- Fundamental
- Price
- RCKY $27.83
- ENGN $3.98
- Analyst Decision
- RCKY Hold
- ENGN Buy
- Analyst Count
- RCKY 1
- ENGN 7
- Target Price
- RCKY $30.00
- ENGN $23.29
- AVG Volume (30 Days)
- RCKY 68.5K
- ENGN 107.0K
- Earning Date
- RCKY 07-29-2025
- ENGN 09-09-2025
- Dividend Yield
- RCKY 2.25%
- ENGN N/A
- EPS Growth
- RCKY 24.23
- ENGN N/A
- EPS
- RCKY 2.48
- ENGN N/A
- Revenue
- RCKY $462,328,000.00
- ENGN N/A
- Revenue This Year
- RCKY $6.67
- ENGN N/A
- Revenue Next Year
- RCKY $4.25
- ENGN N/A
- P/E Ratio
- RCKY $11.14
- ENGN N/A
- Revenue Growth
- RCKY N/A
- ENGN N/A
- 52 Week Low
- RCKY $11.93
- ENGN $2.65
- 52 Week High
- RCKY $34.69
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- RCKY 68.67
- ENGN 61.00
- Support Level
- RCKY $24.68
- ENGN $3.78
- Resistance Level
- RCKY $30.90
- ENGN $4.15
- Average True Range (ATR)
- RCKY 1.41
- ENGN 0.27
- MACD
- RCKY 0.32
- ENGN 0.03
- Stochastic Oscillator
- RCKY 63.45
- ENGN 75.00
About RCKY Rocky Brands Inc.
Rocky Brands Inc acts as a designer, manufacturer, and marketer of premium-quality footwear and apparel. The company's family of brands includes Rocky, Georgia Boot, Durango, Lehigh, Creative Recreation, and the licensed brand Michelin footwear. The company operates its business through three business segments: Wholesale, Retail and Contract Manufacturing. It generates the majority of the revenue from the Wholesale segment.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.